Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 6.88 MB)

  Published:

  12 July 2023

• Final draft guidance committee papers (PDF 1.19 MB)

  Published:

  12 July 2023